Kara MacHleidt

Kara Machleidt, Ph.D. is a Global Strategic Business Lead at Promega Corporation with a background in biochemistry and cell biology. Kara has held various scientific roles at companies like Thermo Fisher Scientific and Vertex Pharmaceuticals, where Kara led projects related to stem cell models for Parkinson's disease, cell-based assay development, and high-throughput screening for oncology and immunology targets. Kara has a strong track record of successfully building and commercializing innovative products in the life sciences industry. Dr. Machleidt's expertise lies in leveraging cutting-edge technologies to advance research and drug discovery efforts.